Screener
Alnylam Pharmaceuticals ALNY Total Rare — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| (In thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total | 89,764 | 80,849 | 164,158 | 147,817 |
| OXLUMO | ||||
| United States | 18,545 | 16,019 | 35,510 | 30,128 |
| Europe | 22,678 | 21,929 | 47,068 | 42,913 |
| Rest of World | 10,899 | 8,924 | 20,865 | 15,920 |
| Total | 52,122 | 46,872 | 103,443 | 88,961 |
| Total Rare | 141,886 | 127,721 | 267,601 | 236,778 |
| Total net product revenues | $1,172,109 | $672,212 | $2,208,236 | $1,140,750 |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's total rare — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported total rare — total revenues of $141.89M in Q2 2026.
- How has Alnylam Pharmaceuticals's total rare — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's total rare — total revenues increased by 11.1% year-over-year, from $127.72M to $141.89M.
- What is the long-term trend for Alnylam Pharmaceuticals's total rare — total revenues?
- Over 2 years (2023 to 2025), Alnylam Pharmaceuticals's total rare — total revenues has grown at a 23.3% compound annual growth rate (CAGR), from $329.09M to $499.92M.
- What does total rare — total revenues mean?
- This metric represents the aggregate net revenue generated from the company's portfolio of therapeutics specifically indicated for rare diseases. It serves as a key indicator of the commercial success and market penetration of orphan drug assets within the company's specialized product pipeline. Tracking this revenue stream allows investors to evaluate the growth trajectory and sustainability of the company's rare disease business unit independently of broader therapeutic areas.
Ask your AI about Alnylam Pharmaceuticals's total rare — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude